CR8426A - Anticuerpo del receptor anti-igf-i - Google Patents

Anticuerpo del receptor anti-igf-i

Info

Publication number
CR8426A
CR8426A CR8426A CR8426A CR8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A
Authority
CR
Costa Rica
Prior art keywords
antibodies
igf
cancer
receptor
elevated levels
Prior art date
Application number
CR8426A
Other languages
English (en)
Inventor
Singh Rajeeva
J Tavares Daniel
E Dagdigian Nancy
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of CR8426A publication Critical patent/CR8426A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Los anticuerpos, anticuerpos humanizados, anticuerpos recubiertos, fragmentos de anticuerpo, anticuerpos derivatizados y conjugados de los mismos con agentes citotoxicos, que especificamente se enlazan a, e inhiben al receptor del factor I de crecimiento de tipo insulina, antagonizan los efectos de IGF-l, IGF-lI y suero en el crecimiento y supervivencia de celulas de tumor, y que substancialmente carecen de actividad agonista. Los anticuerpos y fragmentos de los mismos por consiguiente se pueden utilizar, opcionalmente en conjuncion con otros agente terapeuticos, en el tratamiento de tumores que expresan niveles elevados del receptor IGF-l, tales como cancer de pecho, cancer de colon, cancer de pulmon, sarcoma sinovial, cancer de prostata, y cancer pancreatico, y los anticuerpos derivatizados se pueden utilizar en el diagnostico y formacion de imagenes de tumores que expresan niveles elevados del IGF-I.
CR8426A 2003-12-08 2006-06-01 Anticuerpo del receptor anti-igf-i CR8426A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody

Publications (1)

Publication Number Publication Date
CR8426A true CR8426A (es) 2007-12-04

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8426A CR8426A (es) 2003-12-08 2006-06-01 Anticuerpo del receptor anti-igf-i

Country Status (13)

Country Link
EP (1) EP1692176A4 (es)
JP (1) JP2008502589A (es)
KR (1) KR20070001883A (es)
CN (1) CN1886424A (es)
AU (1) AU2004303792A1 (es)
BR (1) BRPI0417406A (es)
CA (1) CA2548065A1 (es)
CR (1) CR8426A (es)
EA (1) EA009807B1 (es)
EC (1) ECSP066595A (es)
IL (1) IL174770A0 (es)
MX (1) MXPA06005540A (es)
NO (1) NO20063155L (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012013093A2 (pt) 2009-12-21 2017-12-12 Genentech Inc ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
US8481688B2 (en) * 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
EP2766478A4 (en) 2011-10-10 2015-06-17 Los Angeles Childrens Hospital NEW ASPARAGINASE AND METHOD FOR THE TREATMENT OF DISEASES RELATED TO ASPARAGINE DEPENDENCE
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
BR112019022789A2 (pt) * 2017-05-30 2020-06-09 Teijin Pharma Ltd anticorpo do receptor de anti-igf-i ou fragmento do mesmo ou um derivado do mesmo, molécula de ácido nucleico, vetor de clonagem ou vetor de expressão, célula recombinante, processo de produção de um anticorpo do receptor de anti-igf-i ou fragmento do mesmo ou um derivado do mesmo, composição farmacêutica, medicamento, método para cultivar células derivadas de vertebrados in vitro, e, animal transgênico.
AU2024232344A1 (en) * 2023-03-07 2025-10-02 Akeso Pharma Co., Ltd. Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1135688A2 (en) * 1998-12-04 2001-09-26 Novartis AG Methods and compositions useful for targeting activated vitronectin receptor alpha(nu)-beta(3)
PA8535501A1 (es) * 2001-01-05 2003-07-28 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
CA2514231A1 (en) * 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies

Also Published As

Publication number Publication date
IL174770A0 (en) 2006-08-20
MXPA06005540A (es) 2006-08-17
CA2548065A1 (en) 2005-07-07
EP1692176A4 (en) 2008-11-12
EP1692176A1 (en) 2006-08-23
EA200600931A1 (ru) 2006-10-27
BRPI0417406A (pt) 2007-04-03
ECSP066595A (es) 2006-10-17
NO20063155L (no) 2006-08-11
AU2004303792A1 (en) 2005-07-07
CN1886424A (zh) 2006-12-27
JP2008502589A (ja) 2008-01-31
EA009807B1 (ru) 2008-04-28
KR20070001883A (ko) 2007-01-04

Similar Documents

Publication Publication Date Title
AR061911A1 (es) Anticuerpo antagonista para el tratamiento del cancer
DE60336906D1 (de) Anti-igf-i-rezeptor-antikörper
ES2571235T3 (es) Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
UA94388C2 (ru) Антиинтегриновый иммуноконьюгат и способы лечения с его помощью
AR070862A1 (es) Terapia de combinacion con antagonistas de c- met y her
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
AR061245A1 (es) Composiciones y metodos para la modulacion del desarrollo vascular
GT200600324A (es) Nuevos anticuerpos anti-igf-ir y usos de los mismos
UA99608C2 (en) PDGFRb-SPECIFIC INHIBITORS
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
PT2326665E (pt) Proteínas de fusão não citotóxicas compreendendo muteínas de egf
WO2006099141A3 (en) Anti-mesothelin antibodies
NO20070945L (no) Induksjon av apoptose i tumorceller som uttrykker toll-lignende reseptor
EA032908B1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
AR077241A1 (es) Metodo de tratamiento del cancer conantagonista dll4 y agente quimioterapeutico
WO2011137245A3 (en) Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
ECSP066595A (es) Anticuerpo del receptor anti-igf-i
PE20130460A1 (es) Composiciones y metodos para el diagnostico y tratamiento de tumores
EP1909783A4 (en) ILLUDIN ANALOGUE AS CANCER
EA200601405A1 (ru) Гуманизированное антитело
Shi et al. Antibody-drug conjugates in breast cancer: advances and prospects
ZA202407179B (en) Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
JP2018516230A5 (es)
MD2849G2 (ro) Metodă de tratament al cancerului mamar la pacientele de vârstă înaintată
Sandomenico 3D1, a novel anti-nodal monoclonal antibody to target melanoma

Legal Events

Date Code Title Description
FC Refusal